Gapping up
In reaction to earnings/guidance:
- SMCI +14.3%, FLGT +5.4%, SBNY +5.4%, SI +5.1%, CFG +2.4%, JBHT +2.1%, HOPE +1.4%, NHI +1.2%, FITB +1.1%
Other news:
- CMPI +325.7% (Regeneron Pharma (REGN) to acquire CMPI for $10.50/share in cash)
- AXSM +27.9% (received and agreed to Postmarketing Requirements/Commitments proposed by the FDA with respect to the New Drug Application for its AXS-05 product candidate for the treatment of major depressive disorder)
- GFF +8.8% (agreed to sell Telephonics Corporation to TTM Technologies [TTMI])
- BTAI +7.8% (strategic financing agreements by Oaktree Capital Management L.P. and Qatar Investment Authority)
- ZEN +6.4% (chatter circulates suggesting co has tapped an adviser for a sale process)
- PLUG +5.8% (to supply Walmart with green hydrogen to fuel retailer's fleet of material handling lift trucks)
- AVD +3.9% (files preliminary proxy statement; discloses receipt of director nominations from Cruiser Capital)
- GMAB +1.9% (Q1 net sales of DARZALEX (daratumumab))
- USAS +1.9% (reports Q1 consolidated attributable production totaled approximately 300000 silver ounces and 1274000 silver equivalent ounces)
- BGNE +1.7% (presents updated results from Phase 3 RATIONALE-309 Trial of PD-1 inhibitor tislelizumab in first-line RM-NPC; secondary survival endpoint findings were consistent with interim analysis)
Analyst comments:
- NWE +2% (upgraded to Equal Weight from Underweight at Barclays)
- LULU +1.7% (upgraded to Buy from Hold at Truist)
- CRH +1% (upgraded to Overweight from Equal Weight at Barclays)